Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-440
Closed -$35K 82
2024
Q1
$35K Hold
440
﹤0.01% 65
2023
Q4
$39K Buy
440
+80
+22% +$6.89K ﹤0.01% 64
2023
Q3
$35K Buy
360
+64
+22% +$6.62K ﹤0.01% 63
2023
Q2
$30K Buy
296
+40
+16% +$3.96K ﹤0.01% 59
2023
Q1
$28K Buy
+256
New +$28.3K ﹤0.01% 62

Other funds holding APTV

Antipodes Partners's APTV Position: Q2 2024 in Review

Antipodes Partners sold out of Aptiv (APTV) in Q2 2024, closing a stake of 440 shares — an estimated $35K sold.

Antipodes Partners first reported a position in APTV in Q1 2023 and held it in 5 quarters. The position peaked at $39K in Q4 2023. 737 funds tracked by Wall St. Rank hold APTV as of Q2 2024.

  • Antipodes Partners reported no remaining Aptiv position as of Q2 2024 after selling out during the quarter.
  • Antipodes Partners sold 440 Aptiv shares in Q2 2024, an estimated $35K.
  • Antipodes Partners first reported a position in Aptiv in Q1 2023 and held it in 5 quarters.
  • Antipodes Partners's Aptiv position peaked at $39K in Q4 2023.
  • 737 funds tracked by Wall St. Rank held Aptiv as of Q2 2024.

Based on Antipodes Partners's 13F filing for Q2 2024, filed 5 Aug 2024.